Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates
President Donald Trump has just fired another shot across the bow of the global biopharma industry. And the industry quickly fired back in what promises to be a lively battle over drug prices.
Trump’s HHS proposed Thursday afternoon to drop the current way that Medicare covers drugs under Part B — calculating the average sales price and adding 6% to the providers who manage the drug supply — and switch to a new system that pegs US prices against the much lower rates that have been established by single-payer systems abroad.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
